Unknown

Dataset Information

0

The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry.


ABSTRACT: Hepatitis B virus (HBV) infection is a leading cause of liver cirrhosis, liver cancer, and liver failure, affecting 350 million people worldwide. Currently available anti-HBV drugs include (PEGylated-) interferon-? and nucleos(t)ide analogs, which can cause significant side effects and drug-resistance in many cases of long-term treatment. The lack of a reliable and robust in vitro infection system is a major barrier for understanding the HBV life cycle and discovering novel therapeutic targets. In the present study, we demonstrate that overexpression of the hepatitis B surface antigen binding protein (SBP) in HepG2 cells (HepG2-SBP) resulted in their susceptibility to HBV infection. HepG2-SBP cells supported the uptake of the viral surface protein (HBsAg-preS), HBV-pseudotyped virus, and live HBV in patient sera. Moreover, SBP-mediated HBsAg-preS uptake, and HBV pseudotyped virus infections were efficiently blocked by preS1- and SBP-specific antibodies. These observations suggest that SBP is involved in HBV entry and that HepG2-SBP cells can serve as a cellular model to study the post-binding steps of HBV infection.

SUBMITTER: Sun Y 

PROVIDER: S-EPMC6167546 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry.

Sun Yeping Y   Wang Shanshan S   Yi Yong Y   Zhang Jing J   Duan Zhongping Z   Yuan Kehu K   Liu Wenjun W   Li Jing J   Zhu Yiping Y  

Frontiers in cellular and infection microbiology 20180925


Hepatitis B virus (HBV) infection is a leading cause of liver cirrhosis, liver cancer, and liver failure, affecting 350 million people worldwide. Currently available anti-HBV drugs include (PEGylated-) interferon-α and nucleos(t)ide analogs, which can cause significant side effects and drug-resistance in many cases of long-term treatment. The lack of a reliable and robust <i>in vitro</i> infection system is a major barrier for understanding the HBV life cycle and discovering novel therapeutic ta  ...[more]

Similar Datasets

| S-EPMC2838095 | biostudies-literature
| S-EPMC4577879 | biostudies-literature
| S-EPMC3160407 | biostudies-literature
| S-EPMC9027621 | biostudies-literature
| S-EPMC6401444 | biostudies-literature
| S-EPMC3306379 | biostudies-literature
| S-EPMC8761330 | biostudies-literature
| S-EPMC4918827 | biostudies-other
| S-EPMC3419648 | biostudies-literature
| S-EPMC8895675 | biostudies-literature